Price
$134.98+10.85%Social Signal Score
Analyst Ratings
29 analystsRevenue
$567.78M+10.48%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jason Weidman
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 15,500
- Beta
- 0.83
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 2.87
Financials
Revenue
$567.78M+10.5%Net Income
$927.43M+1418.8%EBITDA
$155.91M+60.0%Free Cash Flow
$126.14M+38.5%EPS (diluted)
$22.28+1613.8%Shares Outstanding (diluted)
41.63M-11.6%Operating Expenses
$263.71MCash & Debt
$430.46MReturn of Capital
$318.87MRevenue by Segment (annual)
$1.99BDividend per Share
$0.34Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.99B | $-905.64M | $-20.30 |
| 2024 | $3.05B | $69.67M | $1.49 |
| 2023 | $2.97B | $356.33M | $7.58 |
| 2022 | $2.79B | $363.14M | $7.74 |
| 2021 | $2.81B | $485.37M | $10.38 |
| 2020 | $2.54B | $335.32M | $7.21 |
| 2019 | $2.60B | $461.47M | $9.99 |
| 2018 | $2.45B | $200.80M | $4.39 |
| 2017 | $2.15B | $152.53M | $3.39 |
| 2016 | $1.87B | $237.38M | $5.48 |
| 2015 | $1.81B | $244.86M | $5.89 |
| 2014 | $1.84B | $187.68M | $4.54 |
| 2013 | $1.70B | $150.88M | $3.67 |
| 2012 | $1.55B | $-190.06M | $-4.65 |
Valuation
TFXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
103+47.62%Social Signal Score
Mentions (32)
- News (RSS)seekingalpha·4d ago·Positive
Teleflex Incorporated (TFX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
View source ↗ - Newsseekingalpha.com·4d ago·Positive
Teleflex Incorporated (TFX) Presents at Jefferies Global Healthcare Conference 2026 Transcript Teleflex Incorporated (TFX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
View source ↗ - News (RSS)seekingalpha·9d ago·Neutral
Teleflex: The Market Is Pricing The Transition, Not The Company Coming Out Of It
View source ↗ - Newsseekingalpha.com·9d ago·Positive
…Coming Out Of It Teleflex is undergoing a portfolio overhaul, with future earnings driven by cost cuts, deleveraging, and share buybacks rather than top-line growth. TFX's adjusted gross margin reached 66.8% in Q3; management raised 2026 adjusted EPS guidance to $7.50–$7.75, viewing this as a minimum. Freesolve and Ezplaz offer significant growth optionality, with Freesolve expanding in the U.S. and Ezplaz targeting a $200M+ market opportunity.
View source ↗ - Newsbusinesswire.com·11d ago·Neutral
Teleflex to Present at the Jefferies Global Healthcare Conference in London WAYNE, Pa.--(BUSINESS WIRE)--Management of Teleflex Incorporated (NYSE: TFX) is scheduled to speak at the Jefferies Global Healthcare Conference in London on Wednesday, November 18, 2026, at 12:00 p.m. (GMT). A live audio webcast of the conference presentation will be available on the investor section of the Teleflex website at teleflex.com. About Teleflex Incorporated As a global provider of medical technologies, Telefl…
View source ↗ - Newsmarketbeat.com·14d ago·Neutral
Teleflex Q3 Earnings Call Highlights Teleflex NYSE: TFX raised its 2026 adjusted earnings outlook after reporting higher third-quarter earnings and a return to growth in its Interventional business, although the company said a planned divestiture could close later than expected.
View source ↗ - News (Marketaux)seekingalpha.com·16d ago·Neutral
Teleflex Incorporated 2026 Q3 - Results - Earnings Call Presentation (NYSE:TFX) 2026-11-06 Teleflex Incorporated 2026 Q3 - Results - Earnings Call Presentation (NYSE:TFX) 2026-11-06
View source ↗ - News (RSS)seekingalpha·17d ago·Positive
Teleflex Incorporated (TFX) Q3 2026 Earnings Call Transcript
View source ↗ - Newsseekingalpha.com·17d ago·Positive
Teleflex Incorporated (TFX) Q3 2026 Earnings Call Transcript Teleflex Incorporated (TFX) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·17d ago·Positive
Teleflex (TFX) Q3 Earnings Surpass Estimates Teleflex (TFX) came out with quarterly earnings of $2.63 per share, beating the Zacks Consensus Estimate of $1.92 per share. This compares to earnings of $3.67 per share a year ago.
View source ↗ - Newsbusinesswire.com·17d ago·Negative
Teleflex Announces Quarterly Dividend WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable December 31, 2026, to shareholders of record at the close of business on November 16, 2026.About Teleflex IncorporatedAs a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of peopl…
View source ↗ - Newsbusinesswire.com·31d ago·Neutral
Teleflex Announces Third Quarter 2026 Earnings Conference Call Information WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, November 5, 2026. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's webs…
View source ↗ - Newsbusinesswire.com·41d ago·Positive
…mpleted in BIOMAG™-LL Clinical Study Evaluating Longer Lengths for Freesolve™ Resorbable Magnesium Scaffold WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the successful completion of patient enrollment in the BIOMAG™-LL Clinical Study, evaluating the safety and clinical performance of the Freesolve™ Resorbable Magnesium Scaffold (RMS) in 35 mm and 40 mm lengths for the treatment of de novo coronary lesions up to…
View source ↗ - Newszacks.com·47d ago·Neutral
TFX or SONVY: Which Is the Better Value Stock Right Now? Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and SONOVA HOLDING (SONVY). But which of these two stocks offers value investors a better bang for their buck right now?
View source ↗ - Newszacks.com·47d ago·Neutral
Is It Prudent to Add Teleflex Stock to Your Portfolio Now? TFX's Vascular growth, Asia expansion and improved leverage support the outlook, but tariffs, input costs and margin pressure remain key risks.
View source ↗ - Newsbusinesswire.com·54d ago·Neutral
… Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the publication of its latest peer-reviewed study in the American Journal of Infection Control demonstrating that Central Venous Catheters (CVCs) protected with Arrowg+ard™ Technology were associated with a statistically significant 70% lower hazard of central …
View source ↗ - Newszacks.com·54d ago·Neutral
Teleflex (TFX) Soars 4.4%: Is Further Upside Left in the Stock? Teleflex (TFX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
View source ↗ - Newszacks.com·72d ago·Neutral
TFX vs. PEN: Which Stock Is the Better Value Option? Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two stocks is more attractive to value investors?
View source ↗ - News (RSS)yahoo·79d ago·Positive
Teleflex (TFX): Guidance Cut Meets A Bigger Buyback Push
View source ↗ - News (Marketaux)insidermonkey.com·79d ago·Positive
Teleflex (TFX): Guidance Cut Meets A Bigger Buyback Push On August 6, Teleflex Incor[+302 characters]
View source ↗ - Newsbusinesswire.com·79d ago·Negative
Teleflex Features Innovative Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System at CIRSE 2026 WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it will showcase innovative technologies at CIRSE 2026 in Copenhagen, reinforcing its commitment to advancing innovation for healthcare providers. Among the featured technologies will be the Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System. This technolog…
View source ↗ - Newszacks.com·86d ago·Neutral
Should You Add Teleflex Stock to Your Portfolio Now? TFX's Vascular growth, Interventional expansion and improved leverage support its outlook, while currency volatility remains a key risk.
View source ↗ - Newszacks.com·88d ago·Positive
TFX or PEN: Which Is the Better Value Stock Right Now? Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?
View source ↗ - Newszacks.com·89d ago·Positive
Is TFX a Buy Now as Valuation Improves but Execution Risks Remain? Valuation is improving for Teleflex, but slower Vascular Intervention integration and margin pressure keep execution risks in focus.
View source ↗ - Newszacks.com·90d ago·Negative
Can Teleflex's OEM Sale and Higher EPS Outlook Reshape 2026 Returns? TFX's $1.5B OEM sale cuts leverage and lifts 2026 EPS guidance, but weaker growth and margin pressure keep the outlook measured.
View source ↗ - News (RSS)seekingalpha·91d ago·Positive
Teleflex: Strong Company Undergoing Messy Transition, Hold
View source ↗ - News (Marketaux)seekingalpha.com·91d ago·Positive
Teleflex: Strong Company Undergoing Messy Transition, Hold (NYSE:TFX) Teleflex Incorporated [+307 characters]
View source ↗ - News (RSS)seekingalpha·91d ago·Neutral
Teleflex: Portfolio Surgery Creates A Better Medtech Compounder
View source ↗ - Newsseekingalpha.com·91d ago·Negative
…r Teleflex is transforming into a focused procedural technology platform, divesting lower-growth units and reinvesting in high-acuity Vascular and Surgical segments. TFX's Vascular and Surgical segments are generating high-single-digit growth, while Interventional segment weakness is attributed to temporary integration challenges. Proceeds from divestitures are funding debt reduction and substantial share repurchases, enhancing per-share earnings potential and financial flexibility.
View source ↗ - Newszacks.com·104d ago·Neutral
TFX vs. PEN: Which Stock Is the Better Value Option? Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?
View source ↗ - Newszacks.com·104d ago·Neutral
Why Teleflex (TFX) International Revenue Trends Deserve Your Attention Evaluate Teleflex's (TFX) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
View source ↗ - Newsmarketbeat.com·105d ago·Neutral
Teleflex Q2 Earnings Call Highlights Teleflex NYSE: TFX reported second-quarter revenue and adjusted earnings above its expectations, supported by strong growth in its Vascular and Surgical businesses, while slower-than-anticipated integration of its acquired Vascular Intervention business weighed on Interventional results.
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $1.92 per share
Typical surprise +11.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$2.63 vs $1.90beat
- Thu, Aug 6$1.76 vs $1.28beat
- Thu, May 7$1.39 vs $1.21beat
- Thu, Feb 26$1.93 vs $3.73miss
- Thu, Nov 6$3.67 vs $3.38beat
- Thu, Jul 31$3.73 vs $3.36beat
Estimates and results for TFX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TFX officers and directors.
- Bought
- $634k
- Sold
- —
6 trades
0 trades
- Haggerty Gretchen Rbought
- Haggerty Gretchen Rbought
- Randle Stuart Abought
- Krakauer Andrew Abought
- Kelly Liambought
- Ryu Jaewonbought
94 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (22d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (28d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Mar 28, 2025 (31d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (37d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 6, 2023 (8d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (32d later)Sell$15,001 - $50,000
- Daniel Goldmanhouse · NY10 · disclosed May 19, 2023 (39d later)Buy$15,001 - $50,000
- Susie Leehouse · NV03 · disclosed Dec 29, 2022 (29d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 8, 2022 (38d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 10, 2022 (36d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 10, 2022 (31d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 8, 2022 (22d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 8, 2022 (28d later)Sell$1,001 - $15,000
- Susie Leehouse · NV03 · disclosed Jul 13, 2021 (15d later)Buy$1,001 - $15,000
- Susie Leehouse · NV03 · disclosed Jan 11, 2021 (39d later)Buy$1,001 - $15,000
- Susie Leehouse · NV03 · disclosed Jan 11, 2021 (26d later)Buy$1,001 - $15,000
- Susie Leehouse · NV03 · disclosed Jan 11, 2021 (34d later)Buy$1,001 - $15,000
- Susie Leehouse · NV03 · disclosed Jun 15, 2020 (27d later)Sell$1,001 - $15,000
- Susie Leehouse · NV03 · disclosed Jun 15, 2020 (48d later)Sell$1,001 - $15,000
- Susie Leehouse · NV03 · disclosed Jan 16, 2020 (20d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
